Study type: Human research · Status: Verified against declared source

Efficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a 3-Month Follow-up of a Prospective, Open Label, Single-Center Study.

Translational stroke research · 2025

Study scale: A prospective, single-center, open-label, non-randomized pilot study with blinded outcome assessment was conducted at the Military Institute of Medicine-National Research Institute in Warsaw, Poland.

Abstract only: Open source record

Product or molecular entity relationships

  • Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

The secondary objectives were to determine the efficacy of Cerebrolysin as compared to the control group in reducing mortality rates (by 3 months) and the risk of ICH (safety outcomes), improving neurological outcome assessed using NIHSS (at 1 day and 7 day), mRS at 7 days and 30 days, proportion of patients with mRS 0–1 at 90 days, and improving activities of daily living (assessed using BI) at days 30 and 90.

Methods

The online version contains supplementary material available at 10.1007/s12975-025-01355-z.

Scale or participants

A prospective, single-center, open-label, non-randomized pilot study with blinded outcome assessment was conducted at the Military Institute of Medicine-National Research Institute in Warsaw, Poland.

Key findings

This study hypothesized that Cerebrolysin, a multimodal neuroprotective agent, enhances the efficacy and safety of mechanical thrombectomy (MT) in both acute ischemic stroke (AIS) and recovery stroke phases in selected patients with good collateral status (CTA-CS 2–3) and effective recanalization (mTICI 2b-3).

Limitations and uncertainty

Cerebrolysin is a biotechnological product which consists of low molecular-weight neuropeptides and free amino acids and it has been shown to successfully pass the BBB.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.